Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemtuzumab Ozogamicin vs Supportive Care in Elderly AML
NCT00091234Phase 3Unknown
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jun 2004
- Primary completion
- Dec 2013
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML) (3 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoints: Proportion of patients able to start continuation therapy and Overall Survival. Status: unknown.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00091234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00091234.